Healthcare [ 6/11 ] | Drug Manufacturers—Specialty & Generic [ 25/148 ]
IE | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 23 | 0.70 Increased by +312.12% | 0.39 Increased by +79.49% |
| May 4, 23 | -0.48 Increased by +52.48% | -0.37 Decreased by -29.73% |
| Mar 30, 23 | -0.46 Decreased by -2.22% | -0.27 Decreased by -70.37% |
| Mar 29, 23 | -0.46 Decreased by -21.05% | -0.27 Decreased by -70.37% |
| Nov 9, 22 | -0.33 Increased by +13.16% | -0.25 Decreased by -32.00% |
| Aug 9, 22 | -1.01 Decreased by -206.06% | -0.41 Decreased by -146.34% |
| May 9, 22 | -0.45 Decreased by -95.65% | -0.43 Decreased by -4.65% |
| Mar 17, 22 | -0.38 Decreased by -100.00% | -0.41 Increased by +7.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 1.50 M Increased by +N/A% | -64.43 M Decreased by -1.56% | Decreased by -4.31 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -30.78 M Decreased by -16.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -27.45 M Decreased by -23.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -20.15 M Increased by +8.44% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -63.44 M Decreased by -224.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -26.42 M Decreased by -96.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | -22.30 M Decreased by -97.74% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -22.00 M Decreased by -88.00% | Decreased by N/A% Decreased by N/A% |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.